Morquio Syndrome (MPS IV) Market CAGR of approximately 6%-7% during 2025-2032

Market Overview
The Morquio Syndrome (MPS IV) market is experiencing consistent growth driven by improved disease awareness, expanding access to enzyme replacement therapy (ERT), advancements in genetic diagnostics, and ongoing clinical research into next-generation therapies. Morquio Syndrome, a rare lysosomal storage disorder, leads to impaired degradation of keratan sulfate, resulting in skeletal abnormalities, growth delays, and multi-systemic complications.

The global Morquio Syndrome market is estimated to be around USD 550-600 million in 2024 and is projected to reach USD 900-950 million by 2032, registering a CAGR of approximately 6%-7% during 2025-2032. This strong growth is primarily attributed to expanding use of approved enzyme replacement therapies, rising newborn screening initiatives, and increased investments in rare-disease drug development.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71659

Market Dynamics
Key Drivers
• Increasing rare-disease awareness and early diagnosis: Greater physician education and expansion of genetic testing are improving identification of Morquio patients.
• Growing adoption of enzyme replacement therapy (ERT): Vimizin (elosulfase alfa) remains the primary approved therapy and drives most of the market revenue.
• Regulatory support for orphan diseases: Incentives such as Orphan Drug Designation and priority review stimulate innovation.
• Expansion of newborn screening programs: More countries are integrating MPS disorders into screening protocols, increasing early detection rates.
• Advances in molecular and metabolic diagnostics: Next-generation sequencing and biomarker-based tests support accurate and early subtype classification.

Restraints
• High cost of enzyme replacement therapy, limiting access in emerging economies.
• Burden of lifelong treatment, requiring weekly IV infusions, which affects compliance and quality of life.
• Limited therapeutic options, as ERT does not fully address skeletal and neurological complications.
• Small patient population, reducing commercial incentives for multiple drug developers.
• Reimbursement challenges, especially in low- and middle-income countries.

Opportunities
• Gene therapy development targeting MPS IV A and B subtypes.
• Improved drug delivery platforms, including intrathecal formulations for better tissue penetration.
• Research into chaperone therapy, substrate reduction therapy, and genome editing to complement or replace ERT.
• Growing collaborations between biotech firms, government authorities, and academic research centres.
• Robust investment in next-generation therapeutics for lysosomal storage diseases.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71659/morquio-syndrome-market

Trend Analysis
Key trends shaping the Morquio Syndrome market include:
• Next-generation ERT and long-acting formulations gaining industry attention to reduce infusion burden.
• Shift toward gene therapy, driven by advances in AAV vector development and preclinical successes.
• Large-scale epidemiological research, improving prevalence estimates and helping in better clinical-trial design.
• Expansion of patient registries, aiding natural-history studies and improving disease-management guidelines.
• Precision diagnostics, enabling accurate subtype detection (MPS IVA vs MPS IVB), which influences therapy eligibility.

Segment Analysis
By Type
• MPS IVA (Type A): Caused by GALNS enzyme deficiency; accounts for the majority of diagnosed cases.
• MPS IVB (Type B): Caused by GLB1 enzyme deficiency; less common and with fewer dedicated treatments.

By Therapy Type
• Enzyme Replacement Therapy (ERT): Vimizim remains the primary therapy for MPS IVA.
• Supportive & Symptomatic Treatment: Orthopedic interventions, respiratory support, physiotherapy, and pain management.
• Pipeline Therapies: Gene therapy, substrate reduction therapy, chaperone therapy, and next-generation biologics.

By Diagnosis
• Genetic Testing and Next-Generation Sequencing
• Enzyme Activity Assays
• Biochemical Testing
• Radiologic and Skeletal Imaging

By End User
• Hospitals and Specialty Treatment Centres
• Diagnostic Laboratories
• Research Institutions
• Homecare Infusion Services

Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71659

Regional Analysis
North America
North America holds the largest share of the market, driven by widespread availability of Vimizim, well-established rare-disease frameworks, strong reimbursement systems, and active research programs. The region's focus on early diagnosis and access to advanced treatments further supports growth.

Europe
Europe is another significant market, supported by rare-disease legislation, enhanced distribution of ERT therapies, and advanced healthcare infrastructure. Countries like Germany, France, and the UK have high diagnosis rates and active participation in clinical trials.

Asia-Pacific
Asia-Pacific is witnessing rapid growth due to rising genetic screening adoption, increased healthcare spending, and government-backed rare-disease initiatives. Japan and South Korea have strong clinical trial activity, while China and India are expanding newborn screening and diagnostic capabilities.

South America & Middle East/Africa
These regions show gradual growth driven by improving healthcare infrastructure and awareness. However, limited reimbursement for high-cost therapies remains a significant barrier.

Market Size and Growth Outlook
The market for Morquio Syndrome treatments is expected to expand significantly over the coming decade. The current market, valued around USD 550-600 million (2024), is projected to grow to USD 900-950 million by 2032, with a CAGR of approximately 6-7%.
Growth is supported by broader access to ERT, rising patient identification, and anticipation of future gene therapy approvals.

Competitive Landscape
The Morquio Syndrome market is dominated by a small number of specialized rare-disease pharmaceutical companies.
Key Companies
• BioMarin Pharmaceutical
• Denali Therapeutics
• Esteve
• Orchard Therapeutics
• JCR Pharmaceuticals
• Greenovation Biotech
• Inventiva Pharma
• Ultragenyx Pharmaceutical

These companies focus on enzyme replacement therapy, gene therapy, and pipeline biologics designed to address the underlying metabolic defect in MPS IV.

Recent Developments
• Progress in AAV-based gene therapy development targeting MPS IVA and MPS IVB.
• Advancements in intrathecal delivery technologies aimed at improving skeletal and neurological efficacy.
• Expansion of global natural-history databases to support clinical-trial readiness.
• Launch of new newborn screening programs for lysosomal storage diseases in several countries.
• Increased investments by rare-disease foundations to accelerate therapeutic innovation.

Future Outlook
The long-term outlook for the Morquio Syndrome market is strong, supported by continuous research and an expanding treatment ecosystem. While current ERT provides partial symptom relief, future therapies-particularly gene therapy and advanced biologics-are expected to significantly enhance clinical outcomes.
The overall market is expected to maintain a CAGR of 6%-7% between 2025 and 2032, driven by:

• Growing availability of ERT
• Expansion of newborn screening
• Rising R&D investments in gene therapy
• Improved diagnostic infrastructure
• Increasing global rare-disease focus

Over the next decade, the Morquio Syndrome treatment landscape is likely to shift from enzyme replacement toward disease-modifying and potentially curative modalities.

This report is also available in the following languages : Japanese (モルキオ症候群市場), Korean (모르키오 증후군 시장), Chinese (莫尔基奥综合征市场), French (Marché du syndrome de Morquio), German (Markt für Morquio-Syndrom), and Italian (Mercato della sindrome di Morquio), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71659

Our More Reports:

Pollen Allergy Market
https://exactitudeconsultancy.com/reports/71346/pollen-allergy-market

Pyoderma Gangrenosum Market
https://exactitudeconsultancy.com/reports/71348/pyoderma-gangrenosum-market

Sarcoidosis Market
https://exactitudeconsultancy.com/reports/71350/sarcoidosis-market

Anti-Glomerular Basement Membrane Market
https://exactitudeconsultancy.com/reports/71352/anti-glomerular-basement-membrane-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.